Why Biomarker Testing?
Because Accurate, Early Detection Changes the Game. It’s the beginning of the end for Alzheimer’s and Parkinson’s.
At Amprion, our mission is to track the prions EARLY. When symptoms start to appear, this is the late stage of Alzheimer’s or Parkinson’s.
With the advance in molecular science, we empower doctors to track the biomarkers early and accurately to diagnose and treat the disease with confidence. Biomarker testing reduces the risk of misdiagnosis and mistreatment, ensures quality treatment for patients, and speeds drug development.
Accurate diagnosis assures treatment confidence and helps you and your doctor better navigate your preventive brain care journey.
The Benefits of Early Treatment
Consider this:
- When a patient receives a drug at the early stage or asymptomatic stage that slows down the progression rate by 30%, this could delay the disease’s onset by a decade or more. By contrast, when the patient receives the same drug at the late stage or symptom stage, the benefit is minimum, if any.
- Even a 100% effective drug would be unlikely to restore either lost memories or full awareness at the late stage (or symptomatic stage). This same drug administered early in the asymptomatic stage would likely prevent the onset of symptoms during the patient’s lifetime!
- Each individual with ParkinZheimer spectrum disease has a unique biomarker profile. This personalized manifestation of the condition requires doctors to treat each individual differently, using a cocktail made of various drugs to target individual biomarker profiles.
Why test for Alzheimer's or Parkinson's when there is no cure yet?
Because these diseases damage the brain over decades and without symptoms. Biomarker testing helps you and your doctors take actions to slow or stop the onset of symptoms. EARLY.
Why test for Alzheimer's or Parkinson's when there is no cure yet?
Because these diseases damage the brain over decades and without symptoms. Biomarker testing helps you and your doctors take actions to slow or stop the onset of symptoms. EARLY.
By delaying the onset of Alzheimer’s by just five years, we see as much as a 42% decrease in the number of people showing active disease, according to the Alzheimer’s Association.
Our Prion Detection Science provides accurate tracking of the prions that drive Alzheimer’s and Parkinson’s, decades before any physical symptoms.
For people who are worried about the early onset of memory, motor, or cognitive decline, Amprion’s diagnostic tests help rule out prion biomarkers, thus reducing unnecessary stress and worrying.
For people who have positive Prion-biomarker test results, you and your doctor can make informed decisions and develop personalized preventive care, including medical and lifestyle changes that aim to delay or stop the loss of memory, motor control, and independence.
Memory loss or movement disorders are often indications of irreversible damage in Alzheimer’s and Parkinson’s.
Early prevention is the key to delay the progression of neurodegenerative diseases.
As we speed through drug innovation, the top priority, for now, is early prevention.
An accurate, early diagnosis plays a significant role for people who work towards slowing or stopping the onset of Alzheimer’s or Parkinson’s symptoms.
As we speed through the drug development trail, the top priority is early prevention.
An accurate, early diagnosis plays a significant role for individuals who work towards slowing or stopping the onset of Alzheimer’s or Parkinson’s symptoms.
Accurate Diagnosis = Game Changing
Did you know that misdiagnosis of neurodegenerative conditions happens too often, even in the hands of the most qualified medical experts?
Studies have shown 20% to 50% of Alzheimer’s, Lewy Body Dementia, Parkinson’s cases are misdiagnosed initially. Misdiagnosis leads to mistreatment. Find out why diagnosing neurodegenerative diseases has been so challenging.
